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Summary 
CD40 plays an important role in B cell activation,  proliferation,  and Ig class switching. The 
signal transduction pathway mediated by CD40 was studied using monoclonal antibody (mAb) 
626.1 to CD40. Burkitt's lymphoma and Epstein-Barr virus-transformed B cell lines and tonsilar 
B lymphocytes were treated with the anti-CD40 mAb for various lengths of time. The early 
events triggered by CD40 were examined by monitoring the changes in tyrosine phosphorylation 
of cellular proteins with anti-phosphotyrosine mAb. Dephosphorylation of specific  proteins ranging 
between 50-110 kD and the appearance of a 28-kD tyrosine phosphorylated protein were seen 
within 30 s in human B cell lines. The dephosphorylation was reversed and the 28-kD protein 
was dephosphorylated in cells stimulated for 1 min. In resting B cells, the appearance of the 
28-kD phosphoprotein was observed in 30 s after the addition of the anti-CD40 mAb. The tyrosine 
phosphorylation of this protein persisted. The patterns of protein tyrosine phosphorylation differed 
from those induced by an anti-immunoglobulin M mAb. The changes in the state of tyrosine 
phosphorylation induced by the anti-CD40 mAb were obviated by mAb to CD45, a protein 
tyrosine phosphatase (PTP) or by the addition of sodium orthovanadate,  a broad PTP inhibitor. 
They were also blocked by protein tyrosine kinase (FFK) inhibitors, herbimycin A and genistein, 
and PKC and protein serine/threonine kinase inhibitors, H7 and HA1004. In addition, the alteration 
in the tyrosine phosphorylation ofPTKs Lyn, Fyn, and Syk was directly demonstrated. Engagement 
of CD40 for 30 s induced a transient decrease in tyrosine phosphorylation of these PTKs. These 
results indicate that the early events in CD40 signaling involve the complex interaction between 
PTP and protein kinases. 
C 
D40 is a 47-50-kD glycoprotein expressed on B cells 
and some normal and neoplastic epithelial cells including 
follicular dendritic cells and thymic epithelium (1-8).  The 
cDNA sequences of both human and murine CD40 show 
that these glycoproteins  are type I transmembrane proteins 
and contain cysteine-rich extracellular domains followed by 
serine/threonine-rich regions preceding the transmembrane 
domain  (9,  10). They have significant  homology to  the 
members of the nerve growth factor receptor family (9-11). 
CD40 plays an important role in B cell activation, differen- 
tiation, and survival. Heterologous Abs and mAbs to CD40 
induce B cell proliferation  (1, 2, 4, 12, 13) and the engage- 
ment of CD40 by mAb provides a stimulatory signal syner- 
gistic with those delivered by IL-4 or Ab to either surface 
IgM (slgM) 1 or CD20 (2, 14, 15). An anti-CD40 mAb in 
the presence of IL-4 promotes long-term B cell growth (16). 
CD40 also plays a role in the induction of homotypic adhe- 
sion (17, 18). A mAb to CD40 induces bcl-2 expression and 
Parts of these results have been presented in abstract form at the Annual 
Meeting AAP/ASCI/AFCR in Washington DC in May 1993 (1993. Clin. 
Res. 4h277a) and at the Joint Meeting of The American Association of 
Immunologists and the Clinical Immunology Society in Denver, CO in 
May 1993 (1993. J. Immunol. 150:556a). 
1 Abbreviations used in this paper: CD40L, CD40 ligand; PTK, protein 
tyrosine kinase; P-Tyr,  phosphotyrosine;  FFP, protein tyrosine  phosphatase; 
sIgM, surface IgM. 
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mediates the induction oflg class switching. Anti-CD40 mAbs 
induce IgE synthesis in the presence of IL-4 (20, 21) and they 
induce the secretion of various Ig isotypes in the presence 
of different cytokines (22, 23). 
The recent identification and isolation of the CD40 ligand 
(CD40L), gp39, on activated CD4 § T lymphocytes (24--26) 
further underscores the importance of CD40 and its ligand 
in T-B cell interactions.  The recombinant-soluble  CD40L 
stimulates B cell proliferation in the presence of IL-4 and in- 
duces IgE secretion in a manner similar to the engagement 
of CD40 by mAbs (24-28).  Recently, defective expression 
of CD40L  has  been shown  to be responsible for the  im- 
munodeficiency of X-linked hyper-IgM syndrome (29-33), 
further supporting the importance of the CD40-CD40L in- 
teraction in the humoral  arm of the immune  response. 
The early biochemical events triggered through CD40 have 
not been fully delineated.  Similar to slg, cross-linking  of CD40 
stimulates the phosphatidyl inositol pathway (34-37).  Un- 
like mAbs to IgM,  the anti-CD40  mAb fails  to stimulate 
a measurable increase in calcium influx in B cells (13). In ad- 
dition, an anti-CD40 mAb induces an increase in serine/threo- 
nine phosphorylation  within minutes of binding to CD40 
and enhances tyrosine phosphorylation of several substrates 
(37). In light of the complex role of CD40 in B cell activa- 
tion and differentiation, we have investigated the mechanism 
of signal transduction mediated by CD40 with particular em- 
phasis on the early events of this process. 
Materials and Methods 
Cell Preparation.  B  lymphocytes  were isolated  from  tonsils 
obtained from routine tonsillectomy  following the method of  Gruber 
et al.  (13). Mononudear cells were  separated by ficoll-hypaque 
centrifugation.  T cells were depleted by rosetting  with 2-amino- 
ethylisothiouronium  bromide  treated sheep red blood cells. The 
resultant B cells were separated by discontinuous Percoll gradient 
centrifugation  (Pharmacia, Hscataway, NJ). Dense B lymphocytes 
were collected at the interface of 60 and 70% Percoll. This B cell 
population  was typically 96% CD20 positive as determined  by 
FACS  |  analysis (Becton Dickinson and Co., Mountain View, CA). 
Cell Lines.  Burkitt's  lymphoma and EBV-transformed B cell 
lines were maintained in RPMI 1640 supplemented with 10% FCS 
supplemented with 100 U/ml penicillin, 100 #g/m1 streptomycin, 
and  2 mM glutamine.  The Burkitt's  lymphoma  cell lines Raji 
(#+), Daudi (#+,~+),  Ramos (#+), and EBV-transformed cell line 
32al (ce +) were used in our studies. 
raAb and Antisera.  The anti-CD40 mAb 626.1 and the anti- 
CD45 mAb A1.1 were generated in our laboratory as previously 
described (13). A second anti-CD45 mAb BCw, and anti-LFA mAb 
60.3 were generously provided by Dr. J. A. Hansen (Fred Hutch- 
inson Cancer Research Center, Seattle, WA). The anti-IgM-pro- 
ducing hybridoma HB57 was obtained from American Type Cul- 
ture Collection (Rockville, MD). The anti-phosphotyrosine (P-Tyr) 
mAb trill3.4  was characterized previously (38). The antisera to 
the unique NHz-terminal regions of Lyn and Fyn were a generous 
gift from Drs. J. Bolen and A. Burkhardt  (Bristol-Myers Squibb 
Pharmaceutical Research Institute, Princeton, NJ) (39). Additional 
antisera to Lyn and Fyn peptides were also purchased from Upstate 
Biotechnology  Inc. (Lake Placid, NY). The antisera to Syk was 
kindly provided by Dr. R. L. Geahlen (Purdue University, West 
Lafayette, IN) (40). 
Anti-CD40  Stimulation and Detection of Tyrosine Phosphoryla- 
tion.  Several  B cell lines and tonsil]ar B cells were stimulated with 
mAb 626.1 for various amounts of time. The cells were lysed in 
10 raM Tris-HCl, pH 8, 150 mM NaCI,  1% NP-40, 1% glycerol, 
and  1 mM EDTA containing  1 mM PMSF, 1 mM Na3VO4, 1 
#g/ml leupeptin, 1 #g/ml trypsin inhibitor, and 0.2 U/ml aprotinin. 
In certain experiments, 0.1% SDS was included in the extraction 
buffer. Western blots were performed using biotinylated anti-P-Tyr 
mAb 171"113.4, which recognizes P-Tyr with little reactivity to P-Ser 
or P-Thr. The blots were counter-stained with avidin conjugated 
with horseradish peroxidase and developed with the enhanced che- 
miluminescence kit (ECL; Amersham Corp., Arlington  Heights, 
IL). The anti-P-Tyr mAb 4G-10 (Upstate Biotechnology Inc.) was 
used during the early stage of the investigation, mAb PTl13.4 and 
4G-10 yielded similar results. A similar experimental procedure was 
adopted after stimulation  with the anti-IgM  mAb HB57. Equal 
loading in each well was determined by protein quantification be- 
fore loading and by staining the nitrocellulose filters with ponceau 
S after electrophoresis. 
Kinase Inhibitors.  The cell lines were incubated in the presence 
of herbimycin A (7 #g/ml), genistein  (30 #g/ml),  1-(5-isoquin- 
olinesulfonamide)-2-methylpiperazine  (HT, 12 #g/ml),  or N-(2- 
guanidinoethyl)-5-isoqniniolinesulfonamide  (HA1004, 12 #g/ml) 
obtained from Calbiochem-Behring Corp. (San Diego, CA) for 1 h 
at 37~  The cells were then  stimulated  as above. 
Immunoprecipitation.  The Raji and Ramos cell lines were stimu- 
lated with anfi-CD40  for the specified period of time. The cells 
were washed in cold PBS containing  1 mM sodium orthovandate 
and then lysed as mentioned above. The cell lysates from 107 cells 
were cleared by centrifugation  at 13,000g, and incubated with the 
anti-Lyn, anti-Fyn, or anti-Syk sera followed  by protein A-Sepharose 
beads (Pharmacia) for 4 h at 4~ 
Results 
Rapid Alteration  in  Tyrosine Phosphorylation Induced by the 
Anti-CD40 raAb 626.1,  The anti-CD40 mAb 626.1 was used 
to stimulate 13 cells for various amounts of time. The resulting 
protein  tyrosine phosphorylation  was examined by immu- 
noblot analysis using the anti-P-Tyr mAb. Treatment of the 
B cell lines with the anti-CD40 mAb 626.1 resulted in a time- 
dependent alteration of the tyrosine phosphorylation pattern 
of several proteins  (Fig.  1). 
The addition of the anti-CD40 mAb to the cell line Raji, 
for as little as 30 s, resulted in rapid and transient  dephos- 
phorylation of several proteins ranging between 50 and 110 
kD. This was accompanied by a marked increase in tyrosine 
phosphorylation of an *28-kD protein (Fig.  1 A). By 1 rain 
there was a marked increase in the tyrosine phosphorylation 
of proteins in the 50-60- and 70-80-kD regions and a de- 
crease in the 28-kD protein phosphorylation. Increased phos- 
phorylation was also observed on several proteins in the re- 
gion between 30 and 46 kD. A minor 120-kD band was also 
transiently dephosphorylated. These results were confirmed 
by densitometry scanning of the films. These proteins remain 
tyrosine-phosphorylated after treatment with anti-CD40 for 
up to 30 min (data not shown). These results were consis- 
tently observed in two additional experiments. Similar results 
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phosphoryhtion. The human Burkitt's lymphoma cell lines Raji (.4), Dandi 
(B), and Ramos (C), and dense  tonsillar B cells (D) were treated with 
the anti-CD40 mAb 626.1. Lane ! is untreated ceils. Lanes 2-5 were cells 
treated with mAb 626.1 for 30 s, 1, 5, or 10 min, respectively. The reac- 
tion was stopped with cold PBS containing 1 mM Na~VO4. The cells 
were lysed in 1% NP-40 buffer supplemented with 0.4 mM ~,  I mM 
PMSF,  1 mM Na3VO4,  1/~g/rnl leupeptin,  1 /~g/ml trypsin inhibitor, 
and 0.2 U/ml aprotinin. The cell lysates (20 ~g/lane) were electropho- 
resed by SDS-PAGE, transferred to nitrocellulose, and then analyzed by 
Western blot using the anti-P-Tyr mAb PTl13.4 followed by ECL chemi- 
luminescence detection. These results are representative of three experiments. 
were obtained in two experiments  with another anti-P-Tyr 
mAb, 4G-10. 
Two other Burkitt's lymphoma cell lines, Daudi (IgM*) 
and Ramos  (IgM +) were also studied (Fig.  1, B  and C). 
Their phosphorylation and dephosphorylation patterns differ 
from that of Raji cells. In addition to the transient  appear- 
ance of the tyrosine-phosphorylated  28-kD protein, the cell 
line Daudi exhibited a reversal  of the intensities of two tyrosine- 
phosphorylated bands of-56 and 59 kD during the first 30 s 
of stimulation. There was a transient increase in phosphory- 
lation of proteins in the range of 70-80 and 30-40-kD which 
peaked at 1 rain. In the case of the ceU line Ramos, treatment 
with the anti-CD40 mAb for 30 s induced the increased phos- 
phorylation of proteins of *50-53 kD accompanied simul- 
taneously by the appearance  of tyrosine-phosphorylated 28-kD 
proteins.  The apparent  increase in phosphorylation in this 
region differs from the rapid dephosphorylation observed in 
the Raji cells. Although not marked, there was transient de- 
phosphorylation of a 80-kD protein. After l-rain of incuba- 
tion with the anti-CD40 mAb, the tyrosine-phosphorylated 
28-kD  protein  was  not  detected and there was  increased 
1925  Faris et al. 
staining  of substrates  ranging between 90 and 120 kD by 
the anti-P-Tyr mAb. Treatment of an IgA producing EBV- 
transformed B cell line 32al with the anti-CD40 mAb yielded 
a similar pattern of dephosphorylation and rephosphoryla- 
tion as in Daudi ceUs (data not shown). Anti-CD40 stimula- 
tion of dense tonsillar B lymphocytes induced a sustained and 
marked increase of phosphorylation of 28- and 32-kD pro- 
teins (Fig. 1 D). There was also an increase in tyrosine phos- 
phorylation of 38- and 42-kD protein substrates. However, 
dense tonsiUar B cells failed to demonstrate the transient de- 
phosphorylation described above in the B cell lines. 
Thus far, the experiments with anti-CD40 stimulation were 
carried out with bivalent IgG.  Further cross-linking  of bi- 
otinylated mAb 626.1 with avidin accderated the changes 
observed in all of the cell lines and tonsillar B cells during 
the 30 s and 1-min time points (data not shown). This ac- 
cderation made it difficult to observe the dephosphorylation 
and the appearance of phosphotyrosinated 28-kD protein in 
some experiments  involving the B cell lines. 
slgM-sediated Tyrosine Phosphorylatioa Differs  from That 
through CD40.  Events induced after  stimulation through 
sIgM have been extensively investigated (34, 35, 39, 41, 42). 
Our above results suggest that the early events of signal trans- 
duction mediated by CD40 differ from those mediated through 
sIg. This was directly demonstrated in cell lines, Ramos and 
Daudi, which have readily demonstrated surface IgM. Treat- 
ment of Ramos with the anti-IgM mAb HB57 resulted in 
the rapid tyrosine phosphorylation of multiple proteins, some 
of which were identified  as 42, 56,  68,  72,  100, 140, and 
180 kD within 30 s (Fig. 2 A). This phosphorylation pat- 
tern persisted throughout the experimental period of 20 rain. 
Treatment of the B cell line Dandi with this anti-IgM mAb 
resulted in tyrosine phosphorylation of 68-, 72-, 100-, 140-, 
and 180-kD proteins  and the increased phosphorylation of 
34-, 42-, 46-, 48-,  56-,  and 60-kD proteins within 30 s of 
the addition of the mAb although other phosphorylation 
changes were also discernable (Fig. 2 B). These changes were 
persistent  through the 20 min of incubation. These results 
are in agreement with those published by other investigators 
Figure  2.  IgM-induced tyrosine phosphorylation. The human B cell 
lines Ramos (A) and Daudi (B) were untreated (lane 1) or treated with 
the anti-IgM HB 57 for 30 s, 1, 5, 10, or 20 min (lanes 2-6). The tyrosine- 
phosphorylated proteins were analyzed by anti-P-Tyr immunoblotting as 
detailed in Fig.  1.  Similar results were obtained in two additional ex- 
periments. (39, 41). The transient dephosphorylation observed with anti- 
CD40 stimulation was not evident in the anti-IgM stimu- 
lated B cells. In addition, the anti-IgM mAb did not induce 
transient tyrosine phosphorylation of the 28-kD protein (com- 
pare Figs. 1 and 2). The anti-IgM mAb did not induce de- 
tectable changes in tyrosine phosphorylation of cellular pro- 
teins in Raji cells. This may be due to a low levd of surface 
IgM expression in this ceil line (data not shown). 
Effect of Protein Kinase Inhibitors on  CD40.mediated Sig- 
naling.  To further ducidate the mechanism of signal trans- 
duction through CD40, the effect of several kinase inhibi- 
tors,  i.e.,  herbimycin  A,  genistein,  HT,  and HA1004  was 
studied. Incubation of Raji cells with these inhihitors alone 
under our experimental conditions did not induce detectable 
changes in the tyrosine phosphorylation pattern of ceUular 
proteins.  Treatment  of Raji ceUs with the protein tyrosine 
kinase (PTK) inhibitors, herbimycin A or genistein, prevented 
the anti-CD40-induced phosphorylation of the 28-kD pro- 
rein and resulted in a marked inhibition of the anti-CD40-in- 
duced dephosphorylation (Fig. 3, lanes 3 and 4). Treatment 
of the Raji ceil line with the PKC inhibitor, H7, and cAMP- 
and cGMP-dependent protein kinase inhibitor, HA1004, par- 
tially inhibited the anti-CD40-induced tyrosine phosphory- 
lation of the 28-kD protein (Fig. 3, lanes 5 and 6), whereas 
the anti-CD40--induced  dephosphorylation was prevented 
completely. These results are consistent with previous studies 
(36, 37) demonstrating a role of FTK, PKC, and serine/threo- 
nine kinases in the CD40-mediated signaling pathway. In ad- 
dition, interaction between these  kinases and FTP is also 
evident. 
Regulation of CD40-mediated Events by Protein TFosine  Phos- 
phatas~  Because  of our observation that anti-CD40-induced 
proliferation  of resting B ceils (13) is inhibited by the addi- 
tion of anti-CD45 mAb, the role of CD45 in the early events 
of CD40 signaling was investigated. The simultaneous addi- 
tion of anti-CD45 mAb A1.1 and anti-CD40 to the Raji cell 
line blocked the initial events mediated by CD40 (Fig. 4 A). 
Two additional experiments yielded similar results. A similar 
inhibition was observed in the ceil lines Dandi, Ramos, and 
32al as well as in tonsillar B cells (data not shown). These 
Figure  3.  Effect of protein ki- 
nase inhibitors on CD40-mediated 
signal transduction. The Raji cell 
line  was  incubated in  medium 
alone (lanes 1 and 2), or in me- 
dium containing herbimycin A (7 
#g/ml,  hne  3),  genistein  (30 
#g/ml, lane 4),  H7  (12 #g/m1, 
lane 5), or HA1004 (12 #g/m1, 
hne 6) for 1 h. The calls were then 
stimulated with  the anti-CD40 
mAb for 30 s (lanes 2-6). The cell 
lysates  were  separated  by SDS- 
PAGE and analyzed by Western 
blotting using the anti-P--Tyr  mAb 
PTl13.4.  Similar  results  were 
obtained  in  three  separate  ex- 
periments. 
Figure 4.  Effect ofanti-CD45 
mAb and sodium orthovanadate 
on CD40-mediated signal trans- 
duction. (,4) Anti-P-Tyr immuno- 
blotting of cell lysates from un- 
treated Raji cells (lane 1), from 
cells  stimulated  with  the  anti- 
CD40 mAb alone for 30 s (lane 
2) or stimulated simultaneously 
with anti-CD40 and anti-CD45 
mAb for 30 s (lane 3). (B) Anti- 
P-Tyr  immunoblotting  of  cell 
lysates from untreated Raji cells 
(lane I), from cells stimulated with the anti-CD40 mAb for 30 s (lane 
2) and from cells treated with Na3VO~ (400 #M) for 5 min, followed by 
the addition of the anti-CD40 mAb for 30 s (lane 3). Simihr results were 
obtained in two other experiments. 
results were confirmed with another anti-CD45 mAb BCw, 
generously provided by Dr. J. A. Hansen. Both the HLA 
and LFA molecules are highly expressed in B lymphocytes 
in general and in Raji in particular.  Treatment  of Raji cells 
with the anti-CD40 mAh and the mAb to either HLA or 
LFA failed to inhibit the anti-CD40-mediated effects (data 
not shown). 
The participation of protein tyrosine phosphatase(s) (PTP) 
in the events triggered by the anti-CD40 mAb was further 
supported by the inhibitory effect of the PTP inhibitor, so- 
dium orthovanadate,  on anti-CD40-stimulated Raji cells. 
Treatment  with sodium orthovanadate  blocked the appear- 
ance of the phosphorylated 28-kD protein and reduced the 
extent of dephosphorylation initially observed 30 s after the 
addition of the anti-CD40 mAb (Fig. 4 B). These results in- 
dicate that the early events in CD40 signaling are dependent 
on the coordinated interaction of PTK and PTP. 
Anti-CD40  mAb-induced Changes in  TFosine Phasphorfla- 
tion in Lira, Fyn,  and Syk.  The activation  of PTKs after 
receptor binding has been reported.  Some of these receptors 
are  the TCK-CD3  complex,  the  IgM complex,  and the 
PDGF receptor, and several  of these FFK have been identified 
to be members of the src family (39-46).  In addition, the 
sIg and the TCK have been shown to be associated with 
non-src PTK, namely Syk and Zap-70, respectively (40, 47). 
The dephosphorylation of proteins  in the ranges of 50-60 
and 70-80 kD as a result of CD40 engagement suggests that 
some of these proteins may be Lyn (56/53 kD), Fyn (60 kD) 
and Syk (72 kD). Thus, heterologous antisera directed against 
Lyn, Fyn, and Syk (39, 40) were used to immunoblot cell 
lysates separated by SDS-PAGE. Anti-CD40-stimulated and 
-unstimulated ceils were lysed in buffer containing NP-40 
(Fig. 5 A). The cell lysates were analyzed for the expression 
of Lyn, Fyn, and Syk by immunoblots. The relative concen- 
trations  of the Lyn and Fyn proteins remained unaltered in 
Raji during the 30  s and 1 rain of stimulation with the 
anti-CD40 mAb. These results were confn'med using addi- 
tional antisera to Lyn and Fyn. In the case of  Syk, the staining 
intensity of 72-kD bands was maximal in NP-40 ceil lysate 
of Raji ceils stimulated  with the anti-CD40 mAb for 30 s 
and the intensity decreased in the 1-min sample. This varia- 
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tion. (A) NP-40  lysates  from untreated Raji cells (lane 1) and cells stimu- 
lated with the anti-CD40 mAb for 30 s and 1 rain (lanes 2 and 3) were 
analyzed by immunoblotting with antisera to Lyn, Fyn, and Syk. (B) Ly- 
sates from treated and untreated cells were prepared in the presence of 
SDS, and analyzed by immunoblotfing as above. (C) Cell lysates from 
untreated Raji cells  (lane I) and from cells  stimulated  with the anti-CD40 
mAb for 30 s or 1 rain (lanes 2 and 3) were immunoprecipitated with 
antisera to Lyn, Fyn, and Syk. The precipitates  were  dectrophoresed  under 
nonreducing conditions and analyzed by Western blotting using the bi- 
otinyhted anti-P-Tyr mAb. These results are representative of the experi- 
ments. Similar results were obtained in two other experiments, using 
different antisera to Lyn and Fyn. 
tion of staining intensities did not correlate with the protein 
concentrations  of these bands as determined  by Ponceau S 
staining.  The possibility that  the Syk protein  redistributes 
after stimulation of the lymphocytes with the anti-CD40 mAb 
was considered. Lysates of Raji ceils were made in the pres- 
ence of SDS and Western blot analysis  with these heterolo- 
gnus antisera was carried out. As shown in Fig. 5 B, the total 
concentrations of Lyn, Fyn, and Syk did not change as a result 
of anti-CD40  stimulation,  indicating  that redistribution of 
Syk into a NP-40-extractable compartment resulted from the 
anti-CD40  stimulation. 
To assess the tyrosine phosphorylation states of Lyn, Fyn, 
and  Syk proteins,  cell lysates of untreated  and  anti-CD40 
treated Raji cells (107) were immunoprecipitated  with these 
antisera.  The inhibitors  genistein (20/~M)  and  sodium or- 
thovanadate (1 raM) were added to the lysis buffer to inhibit 
in vitro kinase and phosphatase activities after extraction. The 
immunoprecipitates were dectrophoresed, blotted to nitrocd- 
lulose paper, and analyzed with anti-P-Tyr mAb. As shown 
in Fig. 5 C, less P-Tyr staining was observed in immunoprecipi- 
tares by these antisera from Raji calls stimulated for 30 s with 
the anti-CD40  mAb. By 1 min,  the tyrosine phosphoryla- 
tion of Lyn, Fyn, and Syk appeared to return  to the levels 
approximately observed in the untreated samples. In the case 
of Fyn, there were other phosphorylated proteins in the blot. 
These proteins  also appeared in other  two experiments.  It 
remains to be det~rcfined whether these proteins are specifically 
associated with Fyn. Because of the observed anti-CD40-in- 
duced redistribution  of Syk, it appears that  the NP-40-ex- 
tractable Syk underwent transient dephosphorylation and that 
the redistributed Syk was not tyrosine phosphorylated. How- 
ever, the tyrosine-phosphorylation  state of the Syk protein, 
not extractable in NP-40 buffer, cannot be ascertained  in these 
experiments. 
Thus, Lyn, Fyn, and Syk appear to undergo a marked de- 
phosphorylation  during  the initial  30  s of treatment  of B 
ceUs with  the  anti-CD40  mAb  to  be  followed by  rapid 
rephosphorylation of these kinases.  Preliminary experiments 
suggest that the rapid dephosphorylation of Lyn at 30 s was 
accompanied by an increase in in vitro kinase activity in the 
anti-Lyn-precipitated immune complexes (data not shown). 
Tyrosine phosphorylation of Lyn, Fyn, and Syk was also 
examined in Ramos cells stimulated with either anti-CD40 
or anti-IgM  mAb for 30 s and  1 min.  As shown in Fig.  6 
A, the anti-CD40 mAb induced rapid and transient dephos- 
phoryhtion of the Lyn protein. In contrast, the anti-IgM mAb 
induced a time-dependent increase in tyrosine phosphoryla- 
tion of this protein. There was no redistribution of Lyn due 
to either anti-CD40 or anti-IgM stimulation (Fig. 6 B). Simi- 
larly,  transient  anti-CD40-induced  dephosphorylation  in- 
volving Fyn was also observed (data not shown). In the case 
of Syk, the anti-IgM mAb induced readily detectable redis- 
tribution of Syk although this redistribution was much less 
marked in comparison with the effect induced by the anti- 
CD40 mAb (Fig.  6 B). In contrast to the anti-CD40 stimu- 
lation, the anti-IgM mAb induced no dephosphorylation and 
there was a time-dependent increase in the tyrosine phosphory- 
lation in the redistributed and NP-40-extractable Syk. Similar 
results were obtained in an additional experiment. These ob- 
servations further underscore the differences between the signal 
transduction  pathways via CD40  and  IgM. 
Figure 6.  Different  patterns of Lyn and Syk phosphorylation (A) and 
redistribution (/3) in anti-CD40 and anti-IgM-stimuhted cells. (A) Ramos 
cells were stimulated with either anti-CD40 or with anti-IgM mAb for 
O, 30 s, or I rain (lanes I-3). Cell lysates  were immunoprecipitated with 
anti-Lyn and anti-Syk  antisera and analyzed  by immunoblotting with the 
anti-P-Tyr mAb. (B) Untreated or stimuhted Ramos cells were lysed  in 
buffer containing either NP-40 or SDS. The cell  lysates  were analyzed  by 
immunoblotting with antisera to Lyn and Syk. 
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In this study, we have investigated the early events medi- 
ated by the engagement of CD40. Treatment of several Bur- 
kitt's lymphoma and EBV-transformed cell lines with the 
anti-CD40 mAb 626.1 for 30 s induced a rapid dephosphor- 
ylation of proteins ranging between 50 and 110 kD and the 
phosphorylation of a 28-kD protein. Prolonged stimulation 
with the anti-CD40 mAb allowed  the increased  tyrosine 
phosphorylation of proteins at 50-60 and 70-80 kD, whereas 
it resulted in a decrease in 28-kD protein phosphorylation. 
There were variations in the degrees of transient dephosphor- 
ylation among these call lines. However, even in the cell line 
Ramos in which transient dephosphorylation was not readily 
evident,  transient dephosphorylation of certain FFK  was 
demonstrated. Thus, the anti-CD40-induced transient de- 
phosphorylation of certain PTKs and the transient appear- 
ances of a tyrosine-phosphorylated 28-kD protein appear to 
be coupled in early  events  in CD40  signaling in human 
EBV-transformed B cell lines. These events are unique to the 
CD40 signal transduction pathway.  In contrast, treatment 
of dense tonsillar B lymphocytes with anti-CD40 induced 
the sustained tyrosine phosphorylation of 28-kD protein. This 
difference may be due to the inherent differences between 
resting B cells and EBV-transformed B cell lines, or to the 
different  activation stages of the resting B cells. 
The heterogeneity of phosphorylation  patterns in different 
ceil lines and B cells as a result of CD40 engagement has 
been observed by Uckun et al.  (37).  However,  our results 
differ significantly from theirs in that an earlier time point 
(30 s) was included and the experiments were carried  out 
without the addition of secondary cross-linking agents such 
as anti-mouse Ig Abs and PMA.  These differences in ex- 
perimental conditions enable the detection of the early events 
mediated by CD40, including transient dephosphorylation 
and the appearance of 28-kD phosphotyrosinated protein. 
PTK and serine/threonine protein kinase inhibitors have 
been used in the present investigation to implicate their in- 
volvement in early events of CD40 signaling. In vitro kinase 
assay results using the immunoprecipitated CD40 complex 
also provide support for the involvement of both FFKs and 
other protein kinases (data not shown). These results are in 
agreement with those of Uckun et al.  (37). 
CD40 has a long cytoplasmic domain, which lacks tyro- 
sine and contains three serine and three threonine residues 
(9, 10). The protein is constitutively phosphorylated. In an 
in vitro model, an anti-CD40 mAb inhibits the growth of 
CD40 transfectants of routine M12 (B cell) and EL-4 (T cell) 
lines. Mutational analysis has revealed that Thr  TM is essen- 
tial for signal transduction in this system (48). Although this 
is a limited analysis, the results indicate that phosphoryla- 
tion of CD40 by serine/threonine protein kinases is essential 
for CD40 signaling. 
The tyrosine phosphorylation of FrKs Lyn, Fyn, and Syk 
immunoprecipitated by specific antisera was assessed by im- 
munoblotting with anti-P-Tyr mAb. The transient dephos- 
phorylation of these PTK was observed after 30 s of treat- 
ment with the anti-CD40 mAb. Preliminary data in our 
laboratory indicate an increase of kinase activity in immuno- 
precipitated dephosphoryhted  FrK Lyn from Raji cells stimu- 
lated by the anti-CD40 mAb for 30 s. This observation is 
of interest and is consistent with the recent observations de- 
scribed by Nada et al.  (49) and Okada et al. (50).  In their 
studies,  Csk, a novel cytoplasmic FIX has been shown to 
down regulate the src family kinases. In mouse embryo that 
lack  Csk,  the  src  family  kinases,  p60~%  p59~,  and 
p53/56  ly~ have increased kinase activities with a decrease in 
tyrosine phosphorylation. It would be of interest to deter- 
mine if dephosphorylation involves the negative regulatory 
tyrosine residue. 
Anti-CD40 stimulation orb cell lines induced rapid redis- 
tribution of Syk. Without stimulation, Syk was not extract- 
able by a buffer containing NP-40. With stimulation, a con- 
siderable amount of this protein became extractable.  Thus, 
redistribution of Syk to a different cellular component is a 
feature of early events in CD40 signaling. In this investiga- 
tion, redistribution of Syk, though less marked, was also 
shown to be a feature of the IgM-mediated signal transduc- 
tion. In the case of the IgM pathway, there was no transient 
dephosphorylation of Syk, further underscoring the differ- 
ences between the signaling pathways between CD40 and IgM. 
Because Syk is not extractable in a buffer containing NP- 
40, it appears that the phosphorylated 72-80-kD band in un- 
stimulated Raji in Fig.  1 A represents protein(s) other than 
Syk. The recently described B cell-specific I~K, Atk/Bpk 
(51, 52), is likely to migrate in this region. The involvement 
of this kinase in CD40 signaling is supported by our unpub- 
lished finding that  CD40  signaling is  deficient  in EBV- 
transformed B cell lines from patients with X-linked agam- 
maglobulinemia, in whom, Atk/Bpk deficiency has been 
demonstrated. 
Transient early dephosphorylation appears to be a feature 
of the CD40-signaling pathway.  CD45 is the predominant 
receptor-associated protein tyrosine phosphatase expressed on 
lymphocytes (53). The CD45 family constitutes a function- 
ally essential participant in receptor signaling in both T and 
B lymphocytes (44, 45, 54-56). T and B cells lacking CD45 
fail to transduce signals via TCR complex or sIg complex 
upon activation. Transfection of either the CD45 cDNA or 
the cDNA encoding a receptor molecule containing the cy- 
toplasmic portion of CD45, was su~cient to restore TCR 
signal transduction in the CD45-  mutant T  cells (44, 45, 
57-60). Our previous finding of anti-CD45 mAb inhibition 
of anti-CD40-induced B cell proliferation (13) and the present 
finding of anti-CD45 mAb inhibition of anti-CD40-induced 
early dephosphorylation and the transient appearance of the 
28-kD phosphoprotein would support the thesis that CD45 
plays a major role in CD40 signaling.  This hypothesis is in 
general agreement with the overall role of CD45 in T  and 
B lymphocyte activation. Definitive experiments to show the 
direct participation of CD45 in CD40 signaling await  the 
availability of CD45-  mutants of Raji cells. 
As discussed above, kinase activity has been demonstrated 
to be associated with the immunoprecipitated CD40 com- 
1928  CD40-mediated Signal Transduction plex (data not shown). Multiple proteins in the complex are 
phosphorylated in an in vitro assay. Preliminary  studies in 
our laboratory have identified several substrates associated with 
CD40, including the PTK Lyn, phospholipase C 3'1, phos- 
phatidylinositol 3-kinase, and GTPase activating protein. These 
findings are compatible with the recent observation that signal 
transduction via CD40 involves an activation of Lyn, phos- 
phatidylinositol 3-kinase,  and phospholipase C3"2 (61). 
The CD40 cytoplasmic region lacks a tyrosine kinase do- 
main.  Thus,  the  association  of CD40  with  PTKs  occurs 
through adaptor molecules. The rapid tyrosine phosphoryla- 
tion of the 28-kD protein in response to CD40 signaling sug- 
gests that p28 may be such a adaptor molecule. The appear- 
ance of this phosphorylated protein provides an additional 
feature distinguishing  the signaling  of CD40 from that of 
IgM. Further characterization  of this molecule will provide 
further  insights  in the CD40 pathway. 
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